Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Martine Rothblatt sold 9,500 shares of United Therapeutics on May 1 at an average price of $570.58, raising about $5.42M and cutting her ownership by 19% to 40,513 shares (worth roughly $23.12M).
• Market and analyst snapshot: UTHR traded near $581.22 (one‑year range $272.12–$607.89) with a ~$25.5B market cap and a PE of ~20.8, and analysts have a "Moderate Buy" consensus with an average price target of $601.50 (10 Buys, 3 Holds).

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $570.58, for a total value of $5,420,510.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company's stock, valued at $23,115,907.54. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded up $10.82 during trading hours on Monday, reaching $581.22. The company had a trading volume of 354,866 shares, compared to its average volume of 477,395. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89. The business has a fifty day simple moving average of $543.83 and a 200 day simple moving average of $498.27. The firm has a market cap of $25.47 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the company earned $6.19 earnings per share. The business's revenue for the quarter was up 7.4% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Archer Investment Corp lifted its stake in United Therapeutics by 23.9% during the first quarter. Archer Investment Corp now owns 519 shares of the biotechnology company's stock worth $308,000 after purchasing an additional 100 shares during the last quarter. State of Michigan Retirement System lifted its stake in United Therapeutics by 1.7% during the first quarter. State of Michigan Retirement System now owns 11,732 shares of the biotechnology company's stock worth $6,957,000 after purchasing an additional 200 shares during the last quarter. Principal Financial Group Inc. lifted its stake in United Therapeutics by 3.6% during the first quarter. Principal Financial Group Inc. now owns 101,692 shares of the biotechnology company's stock worth $60,301,000 after purchasing an additional 3,534 shares during the last quarter. Chicago Partners Investment Group LLC lifted its stake in United Therapeutics by 15.2% during the first quarter. Chicago Partners Investment Group LLC now owns 1,159 shares of the biotechnology company's stock worth $666,000 after purchasing an additional 153 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in United Therapeutics by 8.9% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 33,624 shares of the biotechnology company's stock worth $19,937,000 after purchasing an additional 2,760 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

UTHR has been the subject of a number of analyst reports. Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research note on Thursday, March 12th. Royal Bank Of Canada lifted their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Finally, Wells Fargo & Company lifted their price objective on United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $601.50.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.